Siga snares $138M US government contract to supply smallpox drug

2023-07-31
FiercePharma
并购上市批准
The Department of Health and Human Services has engaged Siga Technologies to supply $138 million worth of its antiviral drug to treat smallpox.
SigaDepartment of Health and Human Servicescurement contSiga Technologiesillion to supply its smallpox antiviral Tpoxx for stockpilingsmallpox
Siga Technologiesf the contract with the Department of Health and Human Services (HHS), Siga will deliver $113 million worth of its oral version of Tpoxx and $25 million worth of the drug's intravenous form.
Siga expects to fully deliver oral Tpoxx Department of Health and Human Services (HHS)oxSiga 2024 after it fulfills prior contractual obligations foTpoxx treatment, the company said in a July 31 press release.
Siga statement, Phil Gomez, Saga’s Tpoxx executive, noted that the order builds on pTpoxxcontracts for Tpoxx from "13 international customers and the U.S. Department of Defense in 2022."
Tpoxx, which was originally Sagaoved back in 2018 to treat smallpox, picked up a label expansion from the European Medicines Agency last year to treatU.S. Department of Defense
Tpoxxntiviral competes with Chimerix’s Tembexa, which was psmallpox by Emergent BioSolutions last year.European Medicines Agencymonkeypoxcowpox
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。